Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Mayne Pharma Group ( (AU:MYX) ) has provided an update.
Mayne Pharma Group Limited announced the cessation of 102,553 performance rights due to unmet conditions, impacting its issued capital. This cessation reflects the company’s ongoing adjustments in its capital management strategy, potentially affecting stakeholder interests and the company’s market position.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of branded and generic pharmaceutical products. The company is listed on the Australian Securities Exchange (ASX) under the code MYX.
YTD Price Performance: -1.39%
Average Trading Volume: 2,382
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $234.8M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Apple Eyes News App’s Expansion to Earn More Revenues
- FuboTV Stock Is Already Up 333% This Year. How Much Higher Can It Go?
- ‘Don’t Jump on the Bandwagon,’ Says Top Investor About SoundHound AI Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
